Title:
Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin View
Indication:
Epithelial Carcinomas
Location:
Texas Oncology-San Antonio Medical Center
Title:
STAR Ph3 Sinti vs Placebo ESCC View
Description: A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301
Indication:
Esophageal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Essential Thrombocythemia
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Anal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
Ph3 TSR-042, Niraparib Ovarian FIRST View
Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Biliary Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Biliary Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Gall Bladder Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Gall Bladder Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View
Description: A Phase 2 Study of Sitravatinib in Combination with PD-L (1) Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Bladder Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Gastric Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
Biomarker Advcd Uro Cncer and FGFR Aber View
Description: Biomarker Study to Identify Subjects with Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)
Indication:
Bladder Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Bladder Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
PNH Registry View
Description: Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry (M07-001)
Indication:
Hematologic
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Kaposi's Sarcoma
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR PH 2 ASG-22CE Urothelial Cancer View
Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)
Indication:
Bladder Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Kidney Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Bone Mets
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ublituximab+TGR-1202 Cross-over View
Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304
Indication:
Leukemia
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
Ph3 R/R CLL/SLL View
Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)
Indication:
Leukemia
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3b Venetoclax AML View
Description: A Phase 3b, Single-Arm, Multicenter Open-Label Study of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy (M19-072)
Indication:
Leukemia
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Brain Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
Ph1 SGN-LIV1A Metastatic BC View
Description: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer (SGNLVA-001)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I
Title:
Ph2 Ublituximab+ Umbralisib+ Venetoc CLL View
Description: ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)(U2-VEN-207)
Indication:
Leukemia
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
FLEX Registry: Evaluate New Gene Express View
Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Liver Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
Ph 1b2 LIV1A+Pembro 1L mTNBC View
Description: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
Ph 1/1b TNBC, Ovarian View
Description: (AB928CSP0002) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I
Title:
Ph1/2 CDK7 inhibitor HR+ BC View
Description: A Phase 1/2 Study of CT7001 in Combination with Fulvestrant in Patients with Metastatic or Locally Advanced Hormone-Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (CT7001_001)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View
Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph 3 Tuca/Placbo + T-DM1 HER2+ View
Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph1/2 BLU667 thy, NSCLC, Sol tum View
Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC), and Other Advanced Solid Tumors
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View
Description: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT, HOROMONE RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph 1/1b Immunotherapy Combo in NSCLC View
Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
Ph2 Cervical 2L (RaPiDS) View
Description: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)
Indication:
Cervical Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Cervical Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
PH3 Osi +/- Platinum Chemo/Pem NSCLC View
Description: A Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2) (D5169C00001)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View
Description: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Colon Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
Ph3 Fruq + Placebo CC (FRESCO-2) View
Description: A Global, Multicenter, Randomized, Placebo-Controlled Phase 3 Trial to Compare the Efficacy and Safety of Fruquintinib Plus Best Supportive Care to Placebo Plus Best Supportive Care in Patients with Refractory Metastatic Colorectal Cancer (FRESCO-2) (2019-013-GLOB1)
Indication:
Colon Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR KEAP1/NRF2 NSCLC View
Description: CX-839-014 "KEAPSAKE": A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
STAR: PH2 Tuca+ Tras HER2+ CC View
Description: MOUNTAINEER: A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617, SGNTUC-017)
Indication:
Colon Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
STAR BV in older pts w/1L cHL or PTCL View
Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Endometrial Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
PH3 Plac Carbo Pacil Dura +/- Olap DUO-E View
Description: D9311C00001; GOG-3041; ENGOT-EN10: A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)
Indication:
Endometrial Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
TGR-1202 +/- Ublituximab in NHL View
Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma (UTX-TGR-205)
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
STAR Ph2 A+AVD +G-CSF or AOAD in CHL View
Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Esophageal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
Ph3 R/R CLL/SLL View
Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph3 Sinti vs Placebo ESCC View
Description: A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301
Indication:
Esophageal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Malignant Adenoma
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Essential Thrombocythemia
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Myelofibrosis
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 TSR-042, Niraparib Ovarian FIRST View
Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph4 Ixazomib+Lena & Dex MM (MM-6) View
Description: C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)
Indication:
Myelomas
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
Ph1/2 INCB001158 + SC Dara vs Dara SC MM View
Description: A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206)
Indication:
Myelomas
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
Ph 3 Carf w/ Lena/Dex R/R MM (ARROW02) View
Description: (Amgen 20180015) A Randomized, Open-label, Phase 3 StudyComparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2).
Indication:
Myelomas
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 TSR-042, Niraparib Ovarian FIRST View
Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Indication:
Ovarian Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
TTFlds cncmnt w/ PTX recurrent ovn cnr View
Description: ENGOT-ov50 / INNOVATE-3: Pivotal, Randomized, Open-Label Study ofTumor Treating Fields (TTFields, 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer
Indication:
Ovarian Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Gall Bladder Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Ovarian Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Gall Bladder Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Gastric Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
PNH Registry View
Description: Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry (M07-001)
Indication:
Hematologic
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Penile Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
Ph3 TSR-042, Niraparib Ovarian FIRST View
Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Indication:
Peritoneal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Kaposi's Sarcoma
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Kidney Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ublituximab+TGR-1202 Cross-over View
Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304
Indication:
Leukemia
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
Ph3 R/R CLL/SLL View
Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)
Indication:
Leukemia
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3b Venetoclax AML View
Description: A Phase 3b, Single-Arm, Multicenter Open-Label Study of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy (M19-072)
Indication:
Leukemia
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph2 Ublituximab+ Umbralisib+ Venetoc CLL View
Description: ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)(U2-VEN-207)
Indication:
Leukemia
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
STAR Rucaparib v PhysC mCRPC (TRITON3) View
Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Liver Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph3 Nirap+Abirat+Pred mCRPC View
Description: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View
Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Abirat+pred +/- abemaciclib mCRPC View
Description: CYCLONE 2: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
STAR Ph1/2 BLU667 thy, NSCLC, Sol tum View
Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC), and Other Advanced Solid Tumors
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
Ph 1/1b Immunotherapy Combo in NSCLC View
Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I
Title:
Biomarker DNA Defect Men Prostate View
Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Medical Center
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Rectal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
PH3 Osi +/- Platinum Chemo/Pem NSCLC View
Description: A Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2) (D5169C00001)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR: PH2 Tuca+ Tras HER2+ CC View
Description: MOUNTAINEER: A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617, SGNTUC-017)
Indication:
Rectal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View
Description: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Renal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR KEAP1/NRF2 NSCLC View
Description: CX-839-014 "KEAPSAKE": A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Sarcoma
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph1 CX-4945 Basal Cell Carcinoma View
Description: A Phase I, Multi-Center, Open-Label, Treatment Duration Increment, Expansion, Safety, and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07)
Indication:
Skin Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I
Title:
STAR BV in older pts w/1L cHL or PTCL View
Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
Ph1/2 FIH BMS-986249 + Nivo Solid Tumor View
Description: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors
Indication:
Solid Tumors
Location:
Texas Oncology-San Antonio Medical Center
Phase: I
Title:
TGR-1202 +/- Ublituximab in NHL View
Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma (UTX-TGR-205)
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
STAR Ph2 A+AVD +G-CSF or AOAD in CHL View
Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
STAR Ph1/2 BLU667 thy, NSCLC, Sol tum View
Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC), and Other Advanced Solid Tumors
Indication:
Solid Tumors
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
Ph3 R/R CLL/SLL View
Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Malignant Adenoma
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph2 Pemigatinib Solids FGFR View
Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Indication:
Solid Tumors
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Myelofibrosis
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph2 Erdafitinib FGFR Solid Tumors View
Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)
Indication:
Solid Tumors
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
Ph4 Ixazomib+Lena & Dex MM (MM-6) View
Description: C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)
Indication:
Myelomas
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
Ph1/2 INCB001158 + SC Dara vs Dara SC MM View
Description: A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206)
Indication:
Myelomas
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Solid Tumors
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
Ph 3 Carf w/ Lena/Dex R/R MM (ARROW02) View
Description: (Amgen 20180015) A Randomized, Open-label, Phase 3 StudyComparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2).
Indication:
Myelomas
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 TSR-042, Niraparib Ovarian FIRST View
Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Indication:
Ovarian Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
TTFlds cncmnt w/ PTX recurrent ovn cnr View
Description: ENGOT-ov50 / INNOVATE-3: Pivotal, Randomized, Open-Label Study ofTumor Treating Fields (TTFields, 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer
Indication:
Ovarian Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Testicular Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Ovarian Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph1/2 BLU667 thy, NSCLC, Sol tum View
Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC), and Other Advanced Solid Tumors
Indication:
Thyroid Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Thyroid Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph3 FGFR erdafitinib urothelial View
Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)
Indication:
Urothelial Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Penile Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
Ph3 TSR-042, Niraparib Ovarian FIRST View
Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Indication:
Peritoneal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View
Description: A Phase 2 Study of Sitravatinib in Combination with PD-L (1) Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Urothelial Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
Biomarker Advcd Uro Cncer and FGFR Aber View
Description: Biomarker Study to Identify Subjects with Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)
Indication:
Urothelial Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View
Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)
Indication:
Urothelial Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Urothelial Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Rucaparib v PhysC mCRPC (TRITON3) View
Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR PH 2 ASG-22CE Urothelial Cancer View
Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)
Indication:
Urothelial Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph3 Nirap+Abirat+Pred mCRPC View
Description: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Uterine Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Vaginal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Abirat+pred +/- abemaciclib mCRPC View
Description: CYCLONE 2: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Vulvar Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
Biomarker DNA Defect Men Prostate View
Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Medical Center
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Rectal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR: PH2 Tuca+ Tras HER2+ CC View
Description: MOUNTAINEER: A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617, SGNTUC-017)
Indication:
Rectal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Renal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Sarcoma
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph1 CX-4945 Basal Cell Carcinoma View
Description: A Phase I, Multi-Center, Open-Label, Treatment Duration Increment, Expansion, Safety, and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07)
Indication:
Skin Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I
Title:
Ph1/2 FIH BMS-986249 + Nivo Solid Tumor View
Description: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors
Indication:
Solid Tumors
Location:
Texas Oncology-San Antonio Medical Center
Phase: I
Title:
STAR Ph1/2 BLU667 thy, NSCLC, Sol tum View
Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC), and Other Advanced Solid Tumors
Indication:
Solid Tumors
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph2 Pemigatinib Solids FGFR View
Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Indication:
Solid Tumors
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
STAR Ph2 Erdafitinib FGFR Solid Tumors View
Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)
Indication:
Solid Tumors
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Solid Tumors
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Testicular Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph1/2 BLU667 thy, NSCLC, Sol tum View
Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC), and Other Advanced Solid Tumors
Indication:
Thyroid Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II